Pancreas| Volume 167, ISSUE 3, P575-580, March 2020

Download started.


Pre-operative dysglycemia is associated with decreased survival in patients with pancreatic neuroendocrine neoplasms

Published:December 27, 2019DOI:



      Diabetes mellitus is associated with increased risk of pancreatic cancer and impaired postresection survival. For pancreatic neuroendocrine neoplasms, no evidence is available for a similar effect of diabetes mellitus. The aim of this study was to evaluate the glycemic profile in patients with pancreatic neuroendocrine neoplasms and to assess the potential impact of glycemic control on the pathology and long-term outcomes in patients undergoing resection of pancreatic neuroendocrine neoplasms.


      Pancreatic resections from 2001 to 2017 for pancreatic neuroendocrine neoplasms were analyzed from prospective databases. Blood glucose and HbA1c levels were collected from preoperative tests. Preoperative dysglycemia was defined as a blood glucose ≥140 mg% and/or HbA1c ≥6.5%. Uni- and multivariate analyses were performed according to the presence of perioperative dysglycemia. Survival analyses were performed by Kaplan-Meier curves and Cox-proportional hazards method.


      Four hundred and seventeen patients were analyzed. Medical history was positive for diabetes mellitus in 88 (21.1%) patients. Blood glucose evaluation identified 30 additional patients without a prior diagnosis of diabetes mellitus who had preoperative dysglycemia. No differences regarding pathologic characteristics or outcomes were detected between diabetics and non-diabetics. Conversely, patients with dysglycemia had greater rates of metastasis (16.8% vs 27.4%; P = .027) as well as vascular, perineural, and lympho-vascular involvement than those with normal blood glucose (89.2% vs 57.4%; P < .001, 90.0% vs 65.1%; P = .046, and 89.3% vs 61.3; P = .006, respectively). Preoperative dysglycemia was associated with impaired overall survival (hazard ratio = 1.57 [1.01–2.46]) and recurrence-free survival (hazard ratio = 1.78 [1.01–3.12]). By multivariate analysis, preoperative dysglycemia was independently associated with recurrence-free survival (hazard ratio 2.32 [1.29–4.17]), together with lymph-node involvement (hazard ratio = 2.01 [1.14–3.57]) and metastatic disease (hazard ratio = 5.10 [2.73–9.55]).


      Preoperative dysglycemia, but not diabetes mellitus per se, is associated with advanced disease and impaired long-term outcomes in patients undergoing resection for a pancreatic neuroendocrine neoplasm. For those patients, closer surveillance and strict glycemic control are warranted.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Yao J.C.
        • Hassan M.
        • Phan A.
        • et al.
        One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
        J Clin Oncol. 2008; 26: 3063-3072
        • Hallet J.
        • Law C.H.
        • Cukier M.
        • Saskin R.
        • Liu N.
        • Singh S.
        Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.
        Cancer. 2015; 121: 589-597
        • Yao J.C.
        • Lagunes D.R.
        • Kulke M.H.
        Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned.
        Oncologist. 2013; 18: 525-532
        • Partelli S.
        • Bartsch D.K.
        • Capdevila J.
        • et al.
        and the Antibe Consensus Conference participants. ENETS consensus guidelines for standard of care in neuroendocrine tumours: Surgery for small intestinal and pancreatic neuroendocrine tumours.
        Neuroendocrinology. 2017; 105: 255-265
        • Genc C.G.
        • Jilesen A.P.
        • Partelli S.
        • et al.
        A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors.
        Ann Surg. 2018; 267: 1148-1154
        • Partelli S.
        • Javed A.A.
        • Andreasi V.
        • et al.
        The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms.
        Eur J Surg Oncol. 2018; 44: 778-783
        • Jamal M.M.
        • Yoon E.J.
        • Vega K.J.
        • Hashemzadeh M.
        • Chang K.J.
        Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans.
        World J Gastroenterol. 2009; 15: 5274-5278
        • de Jong R.
        • Peeters P.J.H.L.
        • Burden A.M.
        • et al.
        Gastrointestinal cancer incidence in type 2 diabetes mellitus; results from a large population-based cohort study in the UK.
        Cancer Epidemiol. 2018; 54: 104-111
        • Chari S.T.
        • Leibson C.L.
        • Rabe K.G.
        • Ransom J.
        • de Andrade M.
        • Petersen G.M.
        Probability of pancreatic cancer following diabetes: a population-based study.
        Gastroenterology. 2005; 129: 504-511
        • Sharma A.
        • Kandlakunta H.
        • Nagpal S.J.S.
        • et al.
        Model to determine risk of pancreatic cancer in patients with new-onset diabetes.
        Gastroenterology. 2018; 155: 730-739.e3
        • Walter U.
        • Kohlert T.
        • Rahbari N.N.
        • Weitz J.
        • Welsch T.
        Impact of preoperative diabetes on long-term survival after curative resection of pancreatic adenocarcinoma: a systematic review and meta-analysis.
        Ann Surg Oncol. 2014; 21: 1082-1089
        • Vigneri P.
        • Frasca F.
        • Sciacca L.
        • Pandini G.
        • Vigneri R.
        Diabetes and cancer.
        Endocr Relat Cancer. 2009; 16: 1103-1123
        • Andersen D.K.
        • Korc M.
        • Petersen G.M.
        • et al.
        Diabetes, pancreatogenic diabetes, and pancreatic cancer.
        Diabetes. 2017; 66: 1103-1110
        • Leoncini E.
        • Carioli G.
        • La Vecchia C.
        • Boccia S.
        • Rindi G.
        Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis.
        Ann Oncol. 2016; 27: 68-81
        • Godsland I.F.
        Insulin resistance and hyperinsulinaemia in the development and progression of cancer.
        Clin Sci (Lond). 2009; 118: 315-332
        • Cigrovski Berkovic M.
        • Cacev T.
        • Catela Ivkovic T.
        • Zjacic-Rotkvic V.
        • Kapitanovic S.
        New insights into the role of chronic inflammation and cytokines in the etiopathogenesis of gastroenteropancreatic neuroendocrine tumors.
        Neuroendocrinology. 2014; 99: 75-84
        • Pusceddu S.
        • Vernieri C.
        • Di Maio M.
        • et al.
        Metformin use is associated with longer progression-free survival of patients with diabetes and pancreatic neuroendocrine tumors receiving everolimus and/or somatostatin analogues.
        Gastroenterology. 2018; 155: 479-489.e7
        • Valente R.
        • Hayes A.J.
        • Haugvik S.P.
        • et al.
        Risk and protective factors for the occurrence of sporadic pancreatic endocrine neoplasms.
        Endocr Relat Cancer. 2017; 24: 405-414
        • American Diabetes Association
        Diagnosis and classification of diabetes mellitus.
        Diabetes Care. 2010; 33: S62-S69
      1. Bosman F.T. Carneiro F. Hruban R.H. Theise N.D. WHO Classification of Tumours of the Digestive System. 4th edition. World Health Organization, Geneva2010
        • Hank T.
        • Hinz U.
        • Tarantino I.
        • et al.
        Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail.
        Br J Surg. 2018; 105: 1171-1181
        • Ogurtsova K.
        • da Rocha Fernandes J.D.
        • Huang Y.
        • et al.
        IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.
        Diabetes Res Clin Pract. 2017; 128: 40-50
        • Capasso M.
        • Franceschi M.
        • Rodriguez-Castro K.I.
        • et al.
        Epidemiology and risk factors of pancreatic cancer.
        Acta Biomed. 2018; 89: 141-146
        • Berrington de Gonzalez A.
        • Sweetland S.
        • Spencer E.
        A meta-analysis of obesity and the risk of pancreatic cancer.
        Br J Cancer. 2003; 89: 519-523
        • Pothuraju R.
        • Rachagani S.
        • Junker W.M.
        • et al.
        Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting.
        J Exp Clin Cancer Res. 2018; 37: 319
        • Giovannucci E.
        • Harlan D.M.
        • Archer M.C.
        • et al.
        Diabetes and cancer: a consensus report.
        Diabetes Care. 2010; 33: 1674-1685
        • Ryu T.Y.
        • Park J.
        • Scherer P.E.
        Hyperglycemia as a risk factor for cancer progression.
        Diabetes Metab J. 2014; 38: 330-336
        • Zhang A.M.Y.
        • Magrill J.
        • de Winter T.J.J.
        • et al.
        Endogenous hyperinsulinemia contributes to pancreatic cancer development.
        Cell Metab. 2019; 30: 403-404
        • Obazee O.
        • Capurso G.
        • Tavano F.
        • et al.
        Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms.
        Carcinogenesis. 2018; 39: 360-367
        • Scarpa A.
        • Chang D.K.
        • Nones K.
        • et al.
        Whole-genome landscape of pancreatic neuroendocrine tumours.
        Nature. 2017; 543: 65-71
        • Hart P.A.
        • Bellin M.D.
        • Andersen D.K.
        • et al.
        and the Consotrium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.
        Lancet Gastroenterol Hepatol. 2016; 1: 226-237
        • Ewald N.
        • Bretzel R.G.
        Diabetes mellitus secondary to pancreatic diseases (Type 3c)--are we neglecting an important disease?.
        Eur J Intern Med. 2013; 24: 203-206
        • Aggarwal G.
        • Ramachandran V.
        • Javeed N.
        • et al.
        Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in beta cells and mice.
        Gastroenterology. 2012; 143: 1510-1517.e1
        • Chari S.T.
        • Leibson C.L.
        • Rabe K.G.
        • et al.
        Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer.
        Gastroenterology. 2008; 134: 95-101
        • Gyberg V.
        • De Bacquer D.
        • Kotseva K.
        • et al.
        and the EUROASPIRE IV Investigators. Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV–a survey from the European Society of Cardiology.
        Eur Heart J. 2015; 36: 1171-1177
        • Capurso G.
        • Falconi M.
        • Panzuto F.
        • et al.
        Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients.
        Am J Gastroenterol. 2009; 104: 3034-3041
        • Ben Q.
        • Zhong J.
        • Fei J.
        • et al.
        Risk factors for sporadic pancreatic neuroendocrine tumors: A case-control study.
        Sci Rep. 2016; 6: 36073
        • Gallo M.
        • Muscogiuri G.
        • Felicetti F.
        • et al.
        Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes.
        Metabolism. 2018; 78: 141-154
        • Huang X.
        • He D.
        • Ming J.
        • et al.
        High-density lipoprotein of patients with breast cancer complicated with type 2 diabetes mellitus promotes cancer cells adhesion to vascular endothelium via ICAM-1 and VCAM-1 upregulation.
        Breast Cancer Res Treat. 2016; 155: 441-455
        • Quintavalle C.
        • Hindupur S.K.
        • Quagliata L.
        • et al.
        Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib.
        Cell Death Dis. 2017; 8: e3138
        • Kang X.
        • Kong F.
        • Wu X.
        • et al.
        High glucose promotes tumor invasion and increases metastasis-associated protein expression in human lung epithelial cells by upregulating heme oxygenase-1 via reactive oxygen species or the TGF-beta1/PI3K/Akt signaling pathway.
        Cell Physiol Biochem. 2015; 35: 1008-1022
        • Wang L.
        • Bai Y.Y.
        • Yang Y.
        • et al.
        Diabetes mellitus stimulates pancreatic cancer growth and epithelial-mesenchymal transition-mediated metastasis via a p38 MAPK pathway.
        Oncotarget. 2016; 7: 38539-38550
        • Heckman-Stoddard B.M.
        • DeCensi A.
        • Sahasrabuddhe V.V.
        • Ford L.G.
        Repurposing metformin for the prevention of cancer and cancer recurrence.
        Diabetologia. 2017; 60: 1639-1647
        • Zhou P.T.
        • Li B.
        • Liu F.R.
        • et al.
        Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis.
        Oncotarget. 2017; 8: 25242-25250